Suppr超能文献

B细胞流式细胞术交叉配型阳性后肾移植存活率受损。

Impaired renal graft survival after a positive B-cell flow-cytometry crossmatch.

作者信息

Bittencourt M C, Rebibou J M, Saint-Hillier Y, Chabod J, Dupont I, Chalopin J M, Herve P, Tiberghien P

机构信息

ETS de Franche-Comté, Laboratoire d'Histocompatibilité et Thérapeutique Immunomoléculaire, Besançon, France.

出版信息

Nephrol Dial Transplant. 1998 Aug;13(8):2059-64. doi: 10.1093/ndt/13.8.2059.

Abstract

BACKGROUND

The clinical and immunological relevance of a positive B-cell flow-cytometry (B-FCXM) crossmatch in renal transplantation is still controversial.

METHODS

We retrospectively analysed 145 consecutive cadaveric renal transplantations performed from May 1991 to September 1995 in our institution. All grafts were transplanted following a negative IgG T-cell complement-dependent cytotoxicity crossmatch (T-CDCXM). Concomitantly to CDCXM, B-cell and T-cell FCXM were performed and results were expressed as a mean fluorescence index (FI). Two groups were compared: 116 recipients grafted with a negative B-FCXM vs a group of 19 patients grafted with a positive B-FCXM.

RESULTS

The two groups were similar for length of cold ischaemia, donor and recipient's age and degree of HLA mismatching. The proportion of patients with pre-transplant anti-HLA class I antibodies or a retransplantation was significantly increased in the positive B-FCXM group vs the negative B-FCXM group. Recipient survival at 48 months was not significantly different in the two groups. However, graft survival at 12 and 48 months was significantly poorer in the positive B-FCXM than in negative B-FCXM (68% vs 90% at 12 months: P = 0.007, and 57% vs 79% at 48 months: P = 0.02). Within the positive B-FCXM group, no differences were found in pre-transplant anti-HLA class I or II alloimmunization as well as retransplantation frequency between the patients who lost their graft and the patients who did not.

CONCLUSION

Our results suggest that a pretransplant positive B-FCXM is associated with an impaired long-term graft survival in renal allotransplantation.

摘要

背景

肾移植中B细胞流式细胞术(B-FCXM)交叉配型阳性的临床及免疫学相关性仍存在争议。

方法

我们回顾性分析了1991年5月至1995年9月在我院连续进行的145例尸体肾移植。所有移植物均在IgG T细胞补体依赖细胞毒性交叉配型(T-CDCXM)阴性后进行移植。在进行CDCXM的同时,进行B细胞和T细胞FCXM,结果以平均荧光指数(FI)表示。比较两组:116例接受B-FCXM阴性移植的受者与19例接受B-FCXM阳性移植的患者。

结果

两组在冷缺血时间、供受者年龄及HLA错配程度方面相似。与B-FCXM阴性组相比,B-FCXM阳性组移植前抗HLA I类抗体或再次移植患者的比例显著增加。两组48个月时受者生存率无显著差异。然而,B-FCXM阳性组12个月和48个月时的移植物生存率显著低于B-FCXM阴性组(12个月时分别为68%对90%:P = 0.007,48个月时分别为57%对79%:P = 0.02)。在B-FCXM阳性组中,移植物丢失患者与未丢失患者在移植前抗HLA I类或II类同种免疫以及再次移植频率方面未发现差异。

结论

我们的结果表明,移植前B-FCXM阳性与肾同种异体移植中长期移植物存活率受损有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验